JLS Fund: Investments at the Intersection of Psychedelics & Technology
JLS was formed to invest in the exciting intersection of science, technology and neurology, leveraging the enormous potential of plant-based and psychedelic medicines to heal illness and enhance wellness. We focus on the development of drugs for intractable mental and physical conditions and the enabling technology and tools that can accelerate and enhance the delivery of those therapies.
Investments & Advisories
Investments
Parow
Fully integrated, pre-clinical stage biotechnology company developing therapeutics for the accessible treatment of psychiatric diseases
Gilgamesh
Gilgamesh is developing the next generation of central nervous system drugs derived from psychedelics
Diamond therapEutics
Diamond Therapeutics develops psilocybin based medicines while mitigating side effects
Myco systemics
Myco Systemics' mission is to provide systemic scalable myco-cultivation infrastructure to enable producers to meet the demands of the exploding global mushroom market
Tactogen
Tactogen is a public benefit cooperation whose goal is to make transformative medicines safer, more effective, and more accessible
MINDLEAP HEALTH
Mindleap's integration coaches help you to understand and embody the most important parts of your Psychedelic trip, allowing you to create lasting personal transformation.
atai life sciences
ATAI is committed to developing more effective and potentially disease-modifying mental health treatments by researching both psychedelic and non-psychedelic compounds.
universal ibogaine
Universal Ibogaine's mission is to bring proven Ibogaine based clinical treatment protocol to the world and help solve the international opioid crisis
GoodCap
GoodCap is developing effective mushroom-based treatments that open new pathways to a healthier future.
GWELLA
Gwella's focus is on developing transformative consumer brands, products and technologies aimed at elevating people's health and wellbeing.
LUCID NEWS
Lucid News provides informed, honest and transparent journalism that covers the growing integration of psychedelics into society and their broad implications for human wellness.
orthogonal
Orthogonal's mission is to give people access to nature’s most effective health solutions while setting the standard of a new “Farma”: Food as Medicine.
double blind
.
A digital media company covering psychedelics and all they intersect with, from healthcare disparities to the climate crisis
wESANA
.
A life sciences company whose mission is to treat traumatic brain injury and other mental health ailments using psilocybin and other natural therapies.
AWAKN LIFE SCIENCES
Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic new chemical entity drugs and therapies to treat Addiction.
Psilera Bioscience
Psilera is reimagining psychoactive natural products as building blocks for the next generation of neurological therapeutics.
Meet the team
Upcoming Events
Convergence Psychedelics Conference
March 30 - April 2, 2023
JLS Fund’s Lindsay Hoover will be speaking at the Convergence Psychedelics Conference in Los Angeles. She’ll be joined by Hamilton Morris and Dr. Carl Hart, among others. And as a bonus, we’ve created a promo code INSIDERCONV10 (10% off any ticket type).
Benzinga Psychedelics Capital Conference
April 13, 2023
JLS Fund’s Simeon Schnapper will be speaking at the Benzinga Psychedelics Capital Conference in Miami Beach, Florida. The conference, for which Simeon is also a council board member, brings together psychedelics industry leaders and forward thinking investors.
Press
LUCID News
How Awkn is navigating the tough market for investment capital
LUCID News
Psychedelics were the hot topic at the World Economic Forum 2022
LUCID News
How Awkn is navigating the tough market for investment capital
LUCID News
How Awkn is navigating the tough market for investment capital
Toronto Star
He was the Canadian head of the world’s largest pot company. His next big bet? A rare fungus worth thousands a kilogram.
Benzinga
Will Psychedelics Continue To Grow In 2021? Jeff Siegel Shares Insights And Strategies As More Companies Go Public
business insider
Investors are pouring millions into startups that are developing magic mushrooms as medications for conditions like depression and PTSD
Business Insider
Meet the top 14 psychedelics startups raising the most cash to develop new ways of treating depression, addiction, and more
Speaking & Panel Appearances
Investments
Boston Psychedelic Research Group
William Leonard Pickard spoke at a private event
Boston Psychedelic Research Group
William Leonard Pickard spoke at a private event
Boston Psychedelic Research Group
William Leonard Pickard spoke at a private event
PsychedeMIA
William Leonard Pickard spoke at an interdisciplinary symposium at Ohio State University on the future of psychedelic research
Wholecelium
William Leonard Pickard spoke at the first annual "Psychedelic Science and Spirituality Summit" in Stowe, Vermont
Horizons Northwest
William Leonard Pickard spoke at Horizons Northwest's "Perspectives on Psychedelics" conference
Horizons
Lindsay Hoover spoke at Horizons: The Psychedelic Business Forum, the largest and longest-running annual gathering of the psychedelic community in the world
ICPR 2022
Simeon Schnapper spoke on a panel discussing the intersection of psychedelic research, treatments, and investment
PSYCHOACTIVE
Simeon Schnapper on the tensions between philanthropic and for-profit investment, and the challenges and opportunities of this explosive new sector.
European Ibogaine Forum
Political Importance of Ibogaine Development with Rick Doblin, JLS' Simeon Schnapper, and Daniel Callahan
Alchemy
Simeon Schnapper and Lindsay Hoover discuss investing in the psychedelic space and the developing ecosystem of this emerging industry.
Wonderland Miami
William Leonard Pickard presented at a panel entitled: The Pathway to Federal Acceptance
psychedelics today
Lindsay Hoover speaks on Consolidation in the Psychedelics Industry: What to Expect
Cato Institute
William Leonard Pickard and Caleb O. Brown discuss promise and pitfalls in taking psychedelic medicine mainstream.
Benzinga psychedelics capital conference
Lindsay Hoover on differentiating opportunities between private & public companies
REAL VISION
Jeff Siegel on investing in the future of mental healthcare: psychedelics as an asset class
Benzinga Small Cap Conference
Simeon Schnapper moderates a panel on addressing mental health through emerging therapies.
Games for Change Festival
Lindsay Hoover of JLS Fund: Psychedelics as Therapeutics: The Contribution of Game Heuristics
Psyched
Watch Simeon Schnapper on Pysched, the show that explores psychedelics through political, social, and economic perspectives.
Moderated Conferences
INAUGURAL MICRODOSE CONFERENCE
Moderated by Simeon Schnapper
CEO Panel #1: Srinivas Rao MD, PhD- (ATAI) Payton Nyquvest (Numinus), Judy Blumstock (Diamond Therapeutics) Shlomi Raz (Eleusis), Ronan Levy (FieldTrip)
CEO Panel #2: Jackee Stang (Delic), Todd Shapiro (Red Light Holland), Jonathan Sporn MD (Gilgamesh), Martijn Schirp (Synthesis)
The Mushroom: Paul Stamets (Simeon’s hero), Gary Costner (Mycosystemics), David Kurth (Sporing Company), Eric Osborne (MycoMeditations), Dr K Mandrake (Psilocybin Mushroom Bible)
Venture Capital & Funding: Robert Laurie (MAPS), Florian Brand (ATAI), Mark Hazan (Tabula Rasa) Matthew Nordgren (Arcadian Fund), Bek Muslimov (Leafly Tunnel), Richard Skaife (TCF VC)
Know Thyself: Psychedelics & Spirituality
Moderated by Simeon Schnapper
• The State and Future of Psychedelic Therapist Training with Elizabeth M. Nielson, PhD
• MDMA and Transformative Psychedelic Therapy with Dr. Rick Doblin
• MDMA-assisted Psychotherapy: Beyond Symptom Reduction with Dr. Ingmar Gorman
• Healing What Divides Within with Dr. Willa Hall
• PANEL Q&A: MDMA Therapy with Dr. Hall & Dr. Gorman
• MDMA-Assisted Psychotherapy & Social Anxiety Disorder with Dr. Jason Luoma
• MDMA for Couples Therapy Love & Connection Love and connection with Dr. Anne Wagner
• PANEL Q&A: MDMA Therapy with Dr. Luoma & Dr. Wagner
• The Future of MDMA-Assisted Therapy & Availability Dr. Corine de Boer
• Use of Natural Mind-Altering Substances: Cannabis with Dr. Darryl Hudson
• Psychedelics and Depression with Dr. Xiaojue Hu
All proceeds benefit the Tibet House.
Benzinga
Moderator: Simeon Schnapper
Addressing Mental Health Through Emerging Therapies" Panel
Panelists: Dr. Joseph Tucker, CEO, Enveric; Yaron Conforti, CEO, Novamind; Doug Drysdale, CEO, Cybin; Rob Barrow, CEO, MindMed
The National Cannabis Festival
Moderator: Simeon Schnapper
Psychedelics: The Next Frontier for Legalization
Panelists: Mellisa Lavasani, Founder of Plant Medicine Coalition and Proposer of Washington DC’s successful 2020 ballot measure Initiative 81, the Entheogenic Plant and Fungus Policy Act.
Trailblazers: Sedona
May 2022
- Fireside Chat with Simeon Schnapper and Leonard Pickard
- The Investor State of Mind - WTF is happening?- with Michael Gruber
- Invest In The Future Of Medicine - The Psychedelic Investment Opportunity- with Lindsay Hoover
Capital Psychedelic Conference
June 7, 2022
- JLS moderated a panel on alternative medicine and harm reduction featuring government officials and industry experts.
Trailblazers NYC 2022
Moderated by Simeon Schnapper
Revealing The Mind: The Promise + Opportunity of Psychedelics
Panelists: Simeon Schnapper, Sutton King, Hadas Alterman, Liana Gillooly
JLS Podcast: Investing in Psychedelics
Weekly Updates
Stay up to speed with the world of psychedelics with our weekly updates. Sign up.
Contact
Ready to invest? See if you qualify.
Take Our Qualification SurveyIs your company in the psytech space?
Company Inquiry FormHave questions or want to learn more?
General InquiriesContacts
